Charles River Laboratories International, Inc. - CRL STOCK NEWS

Charles River Laboratories (NYSE: CRL) announces the launch of its eXpDNA plasmid platform during Phacilitate Advanced Therapies Week from January 17-20, 2023 in Miami, FL. This platform enhances plasmid development and production efficiency, reducing timelines to five weeks for High Quality plasmids and ten weeks for GMP plasmids. It builds on the company's vast experience in biologics testing, supporting multiple advanced therapy clients across various applications. Notable presentations will occur on January 18 and January 19.

Charles River Laboratories (NYSE: CRL) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 10:30 a.m. PST (1:30 p.m. EST). The presentation will cover strategic focuses, business developments, and recent trends. Investors can access a live webcast through the Investor Relations section of their website, with a replay available for two weeks afterward. Charles River provides vital products and services to pharmaceutical and biotechnology firms, aiding in research and drug development.

Arlington Capital Partners has acquired Charles River Laboratories' Avian Vaccine Services business, establishing a new entity called AVS Bio. This company will operate independently and cater to the biologic manufacturing market. AVS Bio is a leader in supplying specific pathogen-free eggs and laboratory products essential for vaccine development and manufacturing. With approximately 250 employees across over 20 facilities in the US and Europe, AVS Bio aims to expand through new product development and strategic acquisitions. The acquisition signals Arlington's focus on mission-critical inputs in the biologic sector.

Charles River Laboratories (NYSE: CRL) has re-appointed Dr. Craig B. Thompson to its Board of Directors. Dr. Thompson, a former President and CEO of Memorial Sloan-Kettering Cancer Center, served on Charles River's board from 2013 to 2018. His expertise in immuno-oncology and leadership in healthcare will enhance the board's strategic direction. Dr. Thompson aims to support Charles River's mission in drug research and development. His extensive background includes leadership roles in prominent medical institutions and significant contributions to cancer research.

Charles River Laboratories (NYSE: CRL) has launched the Endosafe® Nexus 200™, a robotic endotoxin testing system designed to enhance laboratory productivity. This system enables efficient testing of undiluted and complex samples, leveraging Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology. Key benefits include a reduction in product lead times by 60-70%, minimized human error, and improved data management through integration with Laboratory Information Management Systems (LIMS). This launch addresses the growing demand for high-throughput automated solutions in pharmaceutical manufacturing.

Charles River Laboratories (NYSE: CRL) has launched its first Charles River Accelerator and Development Lab (CRADL) in Chicago, enhancing contract vivarium space for the biopharmaceutical sector in Illinois. Located in Fulton Market, this facility supports both emerging and established companies by providing on-demand laboratory space, fostering rapid project initiation. The CRADL-Explora Vivarium Network now encompasses 28 facilities across key locations, providing over 380,000 square feet of rental capacity, supporting the growth of the biotech ecosystem.

Charles River Laboratories (NYSE: CRL) will present at two significant investor conferences: the Jefferies 2022 London Healthcare Conference on November 16 at 10:20 a.m. GMT and the Evercore ISI 5th Annual HealthCONx Conference virtually on November 30 at 9:40 a.m. ET. Management will discuss the company’s strategic focus and recent business developments. Live webcasts will be available on the Investor Relations section of Charles River's website, with replays accessible for two weeks post-event.

Charles River Laboratories (NYSE: CRL) announced their participation at Neuroscience 2022, where they will present 23 scientific posters on neuroscience advancements. Key presentations include studies on gene therapy, biological markers in Alzheimer's, and Huntington's disease neuronal models. The event takes place from November 12-16 in San Diego, CA, featuring discussions on innovative drug therapies and approaches to neurodegenerative disorders. A notable quote indicates their support of 95% of FDA-approved neuroscience therapies in the last five years.

Charles River Laboratories (NYSE: CRL) has expanded its cell therapy contract development and manufacturing facility in Memphis, Tennessee. The facility now includes nine new processing suites, enhancing its capacity for clinical and commercial cell therapy production. These suites maintain compliance with GMP and international standards, featuring advanced containment designs and high-volume production capabilities. This expansion follows the facility's EMA approval to produce allogeneic cell therapy products, enabling quicker commercialization of transformative medicines.